Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical has reported a strong financial performance for the first half of 2024, with an 11.1% increase in revenue and a significant jump in profits, including a 70.7% rise in profit for the period and a 139.7% surge in profit attributable to the owners. The company also announced an interim dividend of HK3 cents per share, reflecting a robust growth driven by sales of innovative and new products, which saw an increase of 14.8% and 39.6% respectively.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
